Abiraterone - Isotope Labelled Standards
References
FAQ's
References
- Barrie, Susan Elaine; Jarman, Michael; Potter, Gerard Andrew, 17-substituted steroids useful in cancer treatment, British Technology Group Ltd., United Kingdom, US5604213A, February 18, 1997
- Martins, Vanessa; Asad, Yasmin; Wilsher, Nicola; Raynaud, Florence, A validated liquid chromatographic-tandem mass spectroscopy method for the quantification of abiraterone acetate and abiraterone in human plasma, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Volume: 843, Issue: 2, Pages: 262-267, 2006
- Wani, Tanveer A., Highly sensitive ultra-performance liquid chromatography-tandem mass spectrometry method for the determination of abiraterone in human plasma, Analytical Methods, Volume: 5, Issue: 15, Pages: 3693-3699, 2013
Frequently Asked Questions
Why are Abiraterone impurities a concern?
The impurities in Abiraterone affect the drug's efficacy and safety.
What are the types of Abiraterone impurities?
The types of impurities in Abiraterone are categorized into organic impurities, inorganic impurities, residual solvents, and potential genotoxic impurities.
How are Abiraterone impurities detected?
The impurities in Abiraterone were detected using analytical techniques such as high-performance liquid chromatography (HPLC) and LC–UV.
What are the temperature conditions required to store Abiraterone impurities?
Abiraterone impurities are stored at a controlled room temperature between 2-8 ⁰C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.